Rajashri Patil, MD
Internal Medicine · Dallas, TXNPI 1912943960
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$902
- Novo Nordisk$776
- Amgen$711
- Lilly USA, LLC$672
- Pfizer$347
- AbbVie$203
- plus $1K from 22 others
What the payments were for
- Food & beverage$5,091100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $902 |
| Novo Nordisk | 58 | $776 |
| Amgen | 46 | $711 |
| Lilly USA, LLC | 44 | $672 |
| Pfizer | 16 | $347 |
| AbbVie(2 entities) | 12 | $203 |
| Merck | 13 | $186 |
| Amarin Pharma, Inc. | 10 | $167 |
| Bayer | 10 | $148 |
| Kowa Pharmaceuticals America, Inc. | 11 | $135 |
| Boehringer Ingelheim | 7 | $133 |
| Heartflow, Inc. | 2 | $124 |
| Johnson & Johnson | 8 | $114 |
| Exact Sciences | 4 | $73 |
| Currax Pharmaceuticals LLC | 5 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Vivus LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $44 |
| Novartis | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| GSK | 1 | $20 |
| Abbott | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Optos, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$5,107 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $68,828 |
| OzempicSemaglutide | 63 | $64,567 |
| JardianceEmpagliflozin | 67 | $53,896 |
| FarxigaDapagliflozin Propanediol | 53 | $41,701 |
| JanuviaSitagliptin Phosphate | 20 | $22,558 |
| ViberziEluxadoline | 11 | $16,762 |
| LinzessLinaclotide | 14 | $13,676 |
| EliquisApixaban | 12 | $13,273 |
| Repatha SureclickEvolocumab | 12 | $6,064 |
| PremarinEstrogens, Conjugated | 16 | $3,757 |
| SynthroidLevothyroxine Sodium | 42 | $2,967 |
| Icosapent Ethyl | 14 | $2,676 |
| Nebivolol Hcl | 30 | $2,462 |
| Ezetimibe | 80 | $2,458 |
| Levothyroxine Sodium | 236 | $2,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $672 | $68,82867 claims |
| Novo NordiskOzempic | $776 | $64,56763 claims |
| Boehringer IngelheimJardiance | $133 | $53,89667 claims |
| AstraZenecaFarxiga | $902 | $41,70153 claims |
| AbbVieViberzi, Linzess, Synthroid | $203 | $33,40567 claims |
| MerckJanuvia | $186 | $22,55820 claims |
| PfizerEliquis, Premarin | $347 | $17,02928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.